Yamada, YasuhiroUkimura, OsamuKaneko, MasatomoMatsugasumi, ToruFujihara, AtsukoVourganti, SrinivasMarks, LeonardSidana, AbhinavKlotz, LaurenceSalomon, Georgde la Rosette, Jean J. M. C. H.2021-04-072021-04-072021Yamada, Y., Ukimura, O., Kaneko, M., Matsugasumi, T., Fujihara, A., Vourganti, S. ... de la Rosette, J. J. M. C. H. (2021). Moving away from systematic biopsies: Image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review. World Journal of Urology, 39(3), 677-686. https://dx.doi.org/10.1007/s00345-020-03366-x0724-49831433-8726https://dx.doi.org/10.1007/s00345-020-03366-xhttps://hdl.handle.net/20.500.12511/6709Objective To compare the detection rate of clinically significant cancer (CSCa) by magnetic resonance imaging-targeted biopsy (MRI-TB) with that by standard systematic biopsy (SB) and to evaluate the role of MRI-TB as a replacement from SB in men at clinical risk of prostate cancer. Methods The non-systematic literature was searched for peer-reviewed English-language articles using PubMed, including the prospective paired studies, where the index test was MRI-TB and the comparator text was SB. Also the randomized clinical trials (RCTs) are included if one arm was MRI-TB and another arm was SB. Results Eighteen prospective studies used both MRI-TB and TRUS-SB, and eight RCT received one of the tests for prostate cancer detection. In most prospective trials to compare MRI-TB vs. SB, there was no significant difference in any cancer detection rate; however, MRI-TB detected more men with CSCa and fewer men with CISCa than SB. Conclusion MRI-TB is superior to SB in detection of CSCa. Since some significant cancer was detected by SB only, a combination of SB with the TB technique would avoid the underdiagnosis of CSCa.eninfo:eu-repo/semantics/embargoedAccessProstate CancerMagnetic Resonance ImagingTarget BiopsySystematic BiopsyReview Article39367768610.1007/s00345-020-03366-xQ1Q1